Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

August 3, 2020

Study Completion Date

March 14, 2025

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine

DRUG

Nab-paclitaxel

DRUG

Durvalumab

DRUG

Tremelimumab

Trial Locations (27)

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

E1C 6Z8

The Moncton Hospital, Moncton

E1C 8X3

The Vitalite Health Network - Dr. Leon Richard, Moncton

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

N2G 1G3

Grand River Regional Cancer Centre, Kitchener

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

P6B 0A8

Algoma District Cancer Program, Sault Ste. Marie

L2S 0A9

Niagara Health System, St. Catharines

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

M6R 1B5

St. Joseph's Health Centre, Toronto

H7M 3L9

Hopital de la Cite-de-la-Sante, Laval

G6V 3Z1

L'Hotel-Dieu de Levis, Lévis

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

The Jewish General Hospital, Montreal

H4A 3J1

The Research Institute of the McGill University, Montreal

H4J 1C5

Centre Integre Universitaire De Sante Et De Services, Montreal

G1R 2J6

CHUQ-Pavillon Hotel-Dieu de Quebec, Québec

J1H 5N4

Centre hospitalier universitaire de Sherbrooke, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK